Physician profile

Michael A Lee

Family Medicine · Durant, OK

NPI 1124020193

$1,356.49

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $178.22 2021-2022
Lilly USA, LLC $152.74 2021-2022
Novo Nordisk INC $150.28 2019-2022
Janssen Pharmaceuticals, INC $148.76 2021-2022
Astellas Pharma US INC $95.62 2019-2022
Amgen INC. $89.21 2019-2022
Eisai INC. $60.44 2021
Takeda Pharmaceuticals U.S.A., INC. $60.13 2019-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $54.64 2019-2022
Astrazeneca Pharmaceuticals LP $54.52 2020-2022
Currax Pharmaceuticals LLC $38.40 2020-2021
Glaxosmithkline, LLC. $37.55 2020-2022
Sanofi-Aventis U.S. LLC $37.50 2021-2022
Merck Sharp & Dohme LLC $36.01 2021
Pfizer INC. $33.70 2019
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $30.46 2021
Allergan, INC. $28.05 2019-2020
Ironwood Pharmaceuticals, INC $17.90 2020
Biohaven Pharmaceuticals, INC. $16.47 2021
Medtronic, INC. $12.32 2022
Teva Pharmaceuticals USA, INC. $12.14 2020
Nalpropion Pharmaceuticals LLC $11.43 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael A Lee

$1,356.49

in general payments reported 2019-2025

Years
2019-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/50234/michael-a-lee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.